Search
Isoeugenol
go.drugbank.com/drugs/DB14188ApprovedAllergic reactivity to Isoeugenol may be identified with a patch test. … It is also a significant dermatologic sensitizer and allergen, and as a result has been restricted to 200 p.p.m. since 1998 according to guidelines issued by the fragrance industry [A34278].
Ezetimibe
go.drugbank.com/drugs/DB00973ApprovedInvestigational[A15202] By interfering with the intestinal uptake of cholesterol and phytosterols, ezetimibe reduces the delivery of intestinal cholesterol to the liver.[L11347] … The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the
Mixtures: ROSUVINA LEGRAND® E 10/40, ROSUVINA LEGRAND® E 10/20Cipaglucosidase alfa
go.drugbank.com/drugs/DB16708ApprovedInvestigationalCipaglucosidase alfa is conjugated with mannose-6-phosphate (M6P) N-glycans that bind to the cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle, one of the main affected tissues … ,[L45275] and the EMA fully approved the drug on March 27, 2023.
Nintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigational[L8453] Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other … being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.
Gadoteridol
go.drugbank.com/drugs/DB00597ApprovedInvestigationalgadolinium in the brain. … with abnormal vascularity or those thought to disrupt the normal blood-brain barrier.
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigationalRelugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. … [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous
Categories: Gonadotropin Releasing Hormone Receptor AntagonistsAttapulgite
go.drugbank.com/drugs/DB01574ApprovedVet approvedWithdrawnAttapulgite is a magnesium aluminium phyllosilicate which occurs in a type of clay soil common to the Southeastern United States. … When used in medicine, it physically binds to acids and toxic substances in the stomach and digestive tract. For that reason, it has often been used in antidiarrheal medications.
Tranylcypromine
go.drugbank.com/drugs/DB00752ApprovedInvestigationalA propylamine formed from the cyclization of the side chain of amphetamine. … Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTick-borne encephalitis vaccine (whole virus, inactivated)
go.drugbank.com/drugs/DB16611ApprovedInvestigationalTick-borne encephalitis (TBE) is a disease caused by the TBE virus (TBEV), transmitted by ticks from the genus _Ixodes_. The disease course is variable. … [A237520] Due to a paucity of effective safe and effective acute therapeutic agents, vaccination remains the most important defence against TBE in endemic areas.
Synonyms: TBE vaccineClofarabine
go.drugbank.com/drugs/DB00631ApprovedInvestigationalClofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. … It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.